Team:Imperial College London

From 2009.igem.org

(Difference between revisions)

Revision as of 15:44, 23 September 2009

For iGEM 2009 the Imperial College London team present you with The E.ncapsulator; a versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the intestine.

Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been individually optimised by both media and temperature.

The E.ncapsulator provides an innovative method to deliver any biologically synthesisable compound and bypasses the need for expensive storage, packaging and purification processes. The E.ncapsulator is an attractive candidate for commercial pill development and demonstrates the massive manufacturing potential in Synthetic Biology.

@@ Line 1: / Line 1: @@
 {{Imperial/09/TemplateTop}}
 [[Image:II09_Encapsulator_DK_logo.jpg|left|The E.ncapsulator|320px]]
-For iGEM 2009 the Imperial College London team present to you <i>The E.ncapsulator</i>:  A versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the gut.
+For iGEM 2009 the Imperial College London team present you with <i>The E.ncapsulator</i>; a versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the intestine.
-Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been industrially optimised by both media and temperature.
-The <i>E.ncapsulator</i> provides a chassis to deliver any biologically synthesisable compound and bypasses the need for expensive purification, packaging and storage treatments.  This makes it an attractive candidate for commercial pill development and demonstrates the huge potential of synthetic biology in the sphere of manufacturing.
+Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been individually optimised by both media and temperature.
-The <i>E.ncapsulator</i> provides a chassis to deliver any biologically synthesisable compound and bypasses the need for expensive purification, packaging and storage treatments.  This makes it an attractive candidate for commercial pill development and demonstrates the huge potential of synthetic biology in the sphere of manufacturing
+<i>The E.ncapsulator</i> provides an innovative method to deliver any biologically synthesisable compound and bypasses the need for expensive storage, packaging and purification processes. <i>The E.ncapsulator</i> is an attractive candidate for commercial pill development and demonstrates the massive manufacturing potential in Synthetic Biology.
 {{Imperial/09/Division}}